Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 12
1995 13
1996 19
1997 18
1998 9
1999 15
2000 23
2001 18
2002 18
2003 22
2004 26
2005 26
2006 15
2007 22
2008 15
2009 32
2010 18
2011 25
2012 25
2013 32
2014 32
2015 41
2016 34
2017 29
2018 23
2019 25
2020 48
2021 65
2022 53
2023 64
2024 91
2025 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

884 results

Results by year

Filters applied: . Clear all
Page 1
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët JF, Rameix-Welti MA, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T, Haid S, Pietschmann T. Sake SM, et al. Nat Commun. 2024 Feb 8;15(1):1173. doi: 10.1038/s41467-024-45241-y. Nat Commun. 2024. PMID: 38332002 Free PMC article.
Nirsevimab: A Review.
Balbi H. Balbi H. Pediatr Allergy Immunol Pulmonol. 2024 Mar;37(1):3-6. doi: 10.1089/ped.2024.0025. Pediatr Allergy Immunol Pulmonol. 2024. PMID: 38484270 Review.
Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
Manothummetha K, Mongkolkaew T, Tovichayathamrong P, Boonyawairote R, Meejun T, Srisurapanont K, Phongkhun K, Sanguankeo A, Torvorapanit P, Moonla C, Plongla R, Kates OS, Avery RK, Nematollahi S, Permpalung N. Manothummetha K, et al. Clin Microbiol Infect. 2023 Oct;29(10):1272-1279. doi: 10.1016/j.cmi.2023.04.021. Epub 2023 Apr 26. Clin Microbiol Infect. 2023. PMID: 37116860 Free article.
Nirsevimab: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Feb;83(2):181-187. doi: 10.1007/s40265-022-01829-6. Drugs. 2023. PMID: 36577878 Review.
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS; New Vaccine Surveillance Network Collaborators. Moline HL, et al. JAMA Pediatr. 2025 Feb 1;179(2):179-187. doi: 10.1001/jamapediatrics.2024.5572. JAMA Pediatr. 2025. PMID: 39652359
884 results